Mina Sooch - Gemphire Therapeutics President CEO
CEO
Ms. Mina Patel Soochis is President, Chief Executive Officer, Director of the Company. Prior to joining Gemphire Therapeutics, she served from 2012 to 2014 as the CEO of ProNAi, a clinicalstage oncology company, and a board director from its founding in 2004 through 2014. At ProNAi, Ms. Sooch pioneered a new drug modality, DNAi, led the execution of Phase I and II trials on PNT2258 and raised over 70M in Series C and D financing from top tier institutional investors. The last round of 60M was the largest VC financing ever in Michigans history. Prior to her operating role, she has spent over a decade in life sciences VC through founding of Apjohn Ventures and also as EIR at Northcoast Technology Investors. As a VC, she led the sourcing and evaluation of deals across therapeutic areas, the investment terms and syndication, the governance, the followon financings totaling over 300M, and the exits of several life sciences companies. Also, she cofounded three startups . Notable exits from the Apjohn portfolio include the acquisition of ZyStor by BioMarin in 2010, the acquisition of Afmedica by Angiotech Pharmaceuticals in 2005, and the product acquisition from Ikano by UpsherSmith in 2010 since 2014.
Age | 48 |
Tenure | 10 years |
Professional Marks | MBA |
Phone | 734-245-1700 |
Web | http://www.gemphire.com |
Gemphire Therapeutics Management Efficiency
The company has return on total asset (ROA) of (44.9) % which means that it has lost $44.9 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (280.97) %, meaning that it created substantial loss on money invested by shareholders. Gemphire Therapeutics' management efficiency ratios could be used to measure how well Gemphire Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | CEO Age | ||
Francisco Mackenna | Compania Cervecerias Unidas | 57 | |
Matias Bebin | Compania Cervecerias Unidas | N/A | |
Stephen Arcos | Compania Cervecerias Unidas | N/A | |
Pedro Aguado | Compania Cervecerias Unidas | 50 | |
Alvaro Garcia | Compania Cervecerias Unidas | N/A | |
Claudio Melendez | Compania Cervecerias Unidas | N/A | |
Francisco Dominguez | Compania Cervecerias Unidas | 59 | |
Marco Dallolio | Compania Cervecerias Unidas | N/A | |
Alvaro Marambio | Compania Cervecerias Unidas | N/A | |
Fernando Sacchi | Compania Cervecerias Unidas | 59 | |
Hugo Zalazar | Compania Cervecerias Unidas | N/A | |
Fernando Mora | Compania Cervecerias Unidas | N/A | |
Jose Nasrallah | Compania Cervecerias Unidas | 58 | |
Alvaro Roman | Compania Cervecerias Unidas | N/A | |
Claudio Lizana | Compania Cervecerias Unidas | N/A | |
Matias Subercaseaux | Compania Cervecerias Unidas | N/A | |
Carlos Diaz | Compania Cervecerias Unidas | N/A | |
Domingo Manterola | Compania Cervecerias Unidas | 39 | |
Francisco Barriocanal | Compania Cervecerias Unidas | N/A |
Management Performance
Return On Equity | -280.97 | |||
Return On Asset | -44.9 |
Gemphire Therapeutics Leadership Team
Elected by the shareholders, the Gemphire Therapeutics' board of directors comprises two types of representatives: Gemphire Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gemphire. The board's role is to monitor Gemphire Therapeutics' management team and ensure that shareholders' interests are well served. Gemphire Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gemphire Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Bisgaier, Co-Founder, Chief Scientific Officer | ||
Mina Sooch, President CEO | ||
Kenneth Kousky, Independent Director | ||
Andrew Sassine, Independent Director | ||
Jeffrey Mathiesen, CFO | ||
Seth Reno, Chief Commercial Officer | ||
Pedro Lichtinger, Independent Director | ||
Steven Gullans, Interim President Interim CEO, Director | ||
David Lowenschuss, Co-Founder, Chief Legal Officer | ||
Kent Hawryluk, Independent Director | ||
Lee Golden, Chief Medical Officer |
Gemphire Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gemphire Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -280.97 | |||
Return On Asset | -44.9 | |||
Current Valuation | 109.69 M | |||
Shares Outstanding | 14.87 M | |||
Shares Owned By Insiders | 55.90 % | |||
Shares Owned By Institutions | 17.95 % | |||
Number Of Shares Shorted | 142.79 K | |||
Price To Earning | (2.89) X | |||
Price To Book | 2.46 X | |||
EBITDA | (12.09 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gemphire Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gemphire Therapeutics' short interest history, or implied volatility extrapolated from Gemphire Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Gemphire Stock
If you are still planning to invest in Gemphire Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gemphire Therapeutics' history and understand the potential risks before investing.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
CEOs Directory Screen CEOs from public companies around the world | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Money Managers Screen money managers from public funds and ETFs managed around the world |